CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-02 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +5,787 | $8.72 | $50K | 14,897 |
| 2026-09-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −5,387 | $25.69 | $138K | 9,510 |
| 2026-09-02 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −400 | $26.64 | $11K | 9,110 |
| 2026-09-02 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,787 | 117,037 | ||
| 2026-09-01 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +1,452 | $1.86 | $3K | 118,679 |
| 2026-09-01 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −1,452 | $25.47 | $37K | 117,227 |
| 2026-09-01 | Hansen Gwenn Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,452 | 60,858 | ||
| 2026-08-05 | Hansen Gwenn Chief Scientific Officer | Option exercise 10b5-1 | +4,356 | $1.86 | $8K | 121,583 |
| 2026-08-05 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −4,356 | $25.00 | $109K | 117,227 |
| 2026-08-05 | Hansen Gwenn Chief Scientific Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −4,356 | 62,310 | ||
| 2026-08-04 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −1,500 | $23.87 | $36K | 119,838 |
| 2026-08-04 | Hansen Gwenn Chief Scientific Officer | Sale 10b5-1 | −2,611 | $24.64 | $64K | 117,227 |
| 2026-08-04 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −1,794 | $23.89 | $43K | 43,133 |
| 2026-08-04 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −2,967 | $24.65 | $73K | 40,166 |
| 2026-08-03 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +5,787 | $8.72 | $50K | 25,699 |
| 2026-08-03 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −16,589 | $23.05 | $382K | 9,110 |
| 2026-08-03 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −5,787 | 122,824 | ||
| 2026-07-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,750 | 41,342 | ||
| 2026-07-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,858 | 44,200 | ||
| 2026-07-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,572 | 47,772 |
Page 3 of 20 · 381 trades